Barrett's esophagus: proton pump inhibitors and chemoprevention I

G. Triadafilopoulos, A. Taddei, P. Bechi, G. Freschi, M.N. Ringressi, D.R. Degli'Innocenti, F. Castiglione, E. Masini, M. Majewski, G. Wallner, J. Sarosiek, John F. Dillon, R.C. Mccallum, K. Dvorak, A. Goldman, P. Woodland, D. Sifrim, J.E. Richter, M. Vieth, H. NeumannC. Langner, N. Ishimura, Y. Amano, V.N. Felix

    Research output: Contribution to journalArticlepeer-review

    2 Citations (Scopus)


    The following on proton pump inhibitors and chemoprevention in Barrett's esophagus includes commentaries on normalization of esophageal refluxate; the effects of 5-HT agonists on EGF secretion and of lubripristone on chloride channels agents; the role of Campylobacter toxin production; the deleterious effects of unconjugated bile acids; the role of baclofen in nonacid reflux; the threshold for adequate esophageal acid exposure; the effects of proton pump inhibitor (PPI) therapy on normalization of esophageal pH and on cell proliferation; the role of the phenotype of cellular proliferation on the effects of PPI therapy; and the value of Symptom Index and Symptom Association Probability in the evaluation of potential response to treatment. © 2011 New York Academy of Sciences.
    Original languageEnglish
    Pages (from-to)93-113
    Number of pages21
    JournalAnnals of the New York Academy of Sciences
    Issue number1
    Publication statusPublished - Sep 2011
    Event10th OESO World Congress on Barrett's Esophagus - Boston, United States
    Duration: 28 Aug 201031 Aug 2010


    Dive into the research topics of 'Barrett's esophagus: proton pump inhibitors and chemoprevention I'. Together they form a unique fingerprint.

    Cite this